1. Home
  2. SYBX vs VVOS Comparison

SYBX vs VVOS Comparison

Compare SYBX & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • VVOS
  • Stock Information
  • Founded
  • SYBX N/A
  • VVOS 2016
  • Country
  • SYBX United States
  • VVOS United States
  • Employees
  • SYBX N/A
  • VVOS N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • VVOS Medical Specialities
  • Sector
  • SYBX Health Care
  • VVOS Health Care
  • Exchange
  • SYBX Nasdaq
  • VVOS Nasdaq
  • Market Cap
  • SYBX 16.5M
  • VVOS 18.5M
  • IPO Year
  • SYBX N/A
  • VVOS 2020
  • Fundamental
  • Price
  • SYBX $1.20
  • VVOS $2.57
  • Analyst Decision
  • SYBX
  • VVOS Strong Buy
  • Analyst Count
  • SYBX 0
  • VVOS 2
  • Target Price
  • SYBX N/A
  • VVOS $6.30
  • AVG Volume (30 Days)
  • SYBX 6.3K
  • VVOS 79.1K
  • Earning Date
  • SYBX 03-06-2025
  • VVOS 03-31-2025
  • Dividend Yield
  • SYBX N/A
  • VVOS N/A
  • EPS Growth
  • SYBX N/A
  • VVOS N/A
  • EPS
  • SYBX N/A
  • VVOS N/A
  • Revenue
  • SYBX $8,000.00
  • VVOS $15,031,000.00
  • Revenue This Year
  • SYBX N/A
  • VVOS $12.35
  • Revenue Next Year
  • SYBX N/A
  • VVOS $26.02
  • P/E Ratio
  • SYBX N/A
  • VVOS N/A
  • Revenue Growth
  • SYBX N/A
  • VVOS 8.91
  • 52 Week Low
  • SYBX $1.15
  • VVOS $1.91
  • 52 Week High
  • SYBX $1.96
  • VVOS $6.28
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 34.47
  • VVOS 30.17
  • Support Level
  • SYBX $1.27
  • VVOS $3.45
  • Resistance Level
  • SYBX $1.32
  • VVOS $3.36
  • Average True Range (ATR)
  • SYBX 0.05
  • VVOS 0.30
  • MACD
  • SYBX -0.01
  • VVOS -0.08
  • Stochastic Oscillator
  • SYBX 17.81
  • VVOS 13.24

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Share on Social Networks: